Drug intelligence / Profile preview

abetimus sodium

Development stage: Phase 3
Lead developer: Innoviva
Modality: Spiegelmers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapy Plasmids → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Protein Replacement mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Natural RNA Aptamers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Unmodified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Long Non-coding RNA (lncRNA) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

Abetimus sodium is a synthetic immunosuppressant and tolerogen developed for the treatment of systemic lupus erythematosus (SLE), specifically lupus nephritis. It is a tetrameric oligonucleotide conjugate composed of four double-stranded oligodeoxyribonucleotides attached to a nonimmunogenic carrier platform. The drug was designed to induce tolerance in B cells by cross-linking surface antibodies directed against double-stranded DNA (dsDNA), which are implicated in the pathogenesis of lupus nephritis. By binding to these anti-dsDNA antibodies both in circulation and on B cell surfaces, abetimus forms immune complexes that reduce antibody titers and may disable pathogenic B cells[1][3][4][5][6]. Despite showing reductions in anti-dsDNA antibody levels and some clinical benefit in reducing renal flares, pivotal phase III trials failed to demonstrate significant prolongation of time to renal flare compared with placebo[1][8]. Abetimus sodium was never approved or marketed due to lack of sufficient efficacy[2][7]. Developed by: La Jolla Pharmaceutical Company

Brand names: Riquent
Other names: abetimusRentol

Targets

dsDNA-specific BCR (Double-stranded DNA-specific B-cell receptor)

Beyond the preview

Go deeper on abetimus sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abetimus sodium.

Explore the full profile